A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117
Publication
, Conference
Sekeres, MA; Othus, M; List, AF; Odenike, O; Stone, RM; Gore, SD; Litzow, MR; Buckstein, R; Velasco, MR; Gaur, R; Atallah, E; Attar, E ...
Published in: BLOOD
December 6, 2014
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Publisher
AMER SOC HEMATOLOGY
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., … Erba, H. P. (2014). A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. In BLOOD (Vol. 124). AMER SOC HEMATOLOGY.
Sekeres, Mikkael A., Megan Othus, Alan F. List, Olatoyosi Odenike, Richard M. Stone, Steven D. Gore, Mark R. Litzow, et al. “A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.” In BLOOD, Vol. 124. AMER SOC HEMATOLOGY, 2014.
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, et al. A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. In: BLOOD. AMER SOC HEMATOLOGY; 2014.
Sekeres, Mikkael A., et al. “A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.” BLOOD, vol. 124, no. 21, AMER SOC HEMATOLOGY, 2014.
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Velasco MR, Gaur R, Atallah E, Attar E, Appelbaum FR, Erba HP. A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. BLOOD. AMER SOC HEMATOLOGY; 2014.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Publisher
AMER SOC HEMATOLOGY
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology